| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
N-Butyl-1-deoxygalactonojirimycin manufacturers
- Lucerastat
-
-
2026-07-15
- CAS:141206-42-0
- Purity: 98.00%
- Supply Ability: 10g
|
| | N-Butyl-1-deoxygalactonojirimycin Basic information |
| Product Name: | N-Butyl-1-deoxygalactonojirimycin | | Synonyms: | N-Butyl-1-deoxygalactonojirimycin;(2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol;N-(But-1-yl)deoxygalactonojirimycin, (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)-3,4,5-trihydroxypiperidine;(2R,3S,4R,5S)-1-Butyl-2-(hydroxyMethyl)-3,4,5-piperidinetriol;ACT-434964;Lucerastat
(N-Butyldeoxygalactonojirimycin;OGT-923);3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3S,4R,5S)- | | CAS: | 141206-42-0 | | MF: | C10H21NO4 | | MW: | 219.28 | | EINECS: | | | Product Categories: | Glycosidase Inhibitors;Inhibitors | | Mol File: | 141206-42-0.mol |  |
| | N-Butyl-1-deoxygalactonojirimycin Chemical Properties |
| Melting point | 123-124°C | | Boiling point | 394.7±42.0 °C(Predicted) | | density | 1.234±0.06 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | DMF: 20 mg/mL; DMSO: 30 mg/mL; Ethanol: 5 mg/mL; PBS (pH 7.2): 10 mg/mL | | form | A crystalline solid | | pka | 13.72±0.70(Predicted) | | color | White to yellow | | Stability: | Hygroscopic |
| | N-Butyl-1-deoxygalactonojirimycin Usage And Synthesis |
| Chemical Properties | White to Off-White Solid | | Uses | An extremely potent and selective a-D-galactosidase inhibitor. A selective inhibitior of GlcCer synthesis. | | in vivo | Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual-GalA activity[2]. | Animal Model: | Fabry mice (Gla-/0 and Gla-/-, n = 5 or 6 for each gender)[2]. | | Dosage: | 1200 mg/kg/day food admix. | | Administration: | Food admix for 20 weeks. | | Result: | Reduced lipid storage in two major organs affected by FD: mean Gb3 in the kidneys (-33%, p<0.01). and α-galactose- terminated glycosphingolipids in the dorsal root ganglia (-48%, p<0.05). In the liver of the Fabry mice, mean glucosylceramide (GlcCer (24:0)) was reduced (-59%, p<0.001) in addition to Gb3 (24:1) (-37%, p<0.05) demonstrating substrate reduction through GCS inhibition. |
|
| | N-Butyl-1-deoxygalactonojirimycin Preparation Products And Raw materials |
|